FLT3 and acute myeloid leukemia: [47, 48] For example, sorafenib and quizartinib have both demonstrated some efficacy in reducing peripheral blasts in FLT3 ITD mutant AML patients and bone marrow blasts in some cases, but the data from this study indicate that neither of these inhibitors would be effective against blasts harboring FLT3 mutations of D835Y, D835A, D835L+K or I836L+D.